Compare Aspen Aerogels Inc (ASPN) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aspen Aerogels Inc vs 22nd Century Group Inc — how do they compare? Aspen Aerogels Inc trades at $5.25 (market cap $427.65M), while 22nd Century Group Inc trades at $4.24 (market cap $1.46M). The key difference: Aspen Aerogels Inc is far larger — about 292.9× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| ASPN | XXII | |
|---|---|---|
Market Cap | $427.65M | $1.46M |
Sector | Technology | Technology |
52-Week High | $8.82 | $1.85K |
52-Week Low | $2.57 | $3.90 |
Enterprise Value | $382.60M | -$6.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
XXII trades at $4.23, down 2.08% on the day, amid a bearish technical signal. The company's financials show deep losses with a net income margin of -65.76% and negative ROE of -130.19% for 2026. Recent news highlights expansion of its VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. Analyst consensus is 75% buy, but earnings misses in Q4 2025 and Q1 2026 raise execution concerns.
The outlook hinges on VLN's commercial success and FDA regulatory pathway. High cash burn necessitates ongoing financing, evident in 2026's $17M financing inflow. Risks include persistent unprofitability, competitive pressures, and reliance on tobacco harm reduction narrative. Upside depends on revenue scaling and margin improvement from new retail launches.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
